The abstract is read at the publisher; the summary is JClub's.
Oral semaglutide in high-risk type 2 diabetes reduced total first-plus-subsequent 3-point MACE versus placebo (mean ratio 0.86; 95% CI 0.76–0.97).
- Why it matters: Total event analyses can clarify how treatments affect overall disease burden, but the impact of oral semaglutide on subsequent cardiovascular events was not previously known.
- What they did: In the double-blind SOUL trial (June 2019–September 2024; median follow-up 49.5 months) among 9650 participants with type 2 diabetes and atherosclerotic CV disease and/or chronic kidney disease, investigators compared once-daily oral semaglutide (up to 14 mg) with placebo on total 3-P MACE.
- The result: Total 3-P MACE occurred in 683 vs 791 participants (579 first and 104 subsequent vs 668 first and 123 subsequent), and 3-P MACE plus non-CV death had 910 vs 1048 events (mean ratio 0.87; 95% CI 0.79–0.95).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.